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correlated (r = 0.88, p < 0.01) demonstrating an ability to 
detect trends. Objective cough count and subjective cough 
scores modestly correlated (r = 0.46).
Conclusions Cough frequency declines significantly fol-
lowing AE-COPD and the reducing trend can be detected 
using continuous ambient sound recording and novel cough 
classifier software. Objective measurement of cough fre-
quency has the potential to enhance our ability to monitor 
the clinical state in patients with COPD.
Keywords Chronic obstructive pulmonary disease · 
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Introduction
Chronic obstructive pulmonary disease (COPD) is a com-
mon, progressive and debilitating respiratory disease and is 
estimated to become the third leading cause of death world 
wide by 2030. Acute worsening of symptoms including 
shortness of breath and cough are termed acute exacerba-
tions (AE-COPD). AE-COPD often precipitate hospital 
admission and are a source of significant morbidity and 
mortality [1]. Exacerbation prevention and amelioration is 
thus one of the primary aims of COPD treatment.
Cough and sputum production are reported by between 
60 and 80% of patients with COPD [2, 3], and chronic 
cough and mucus hypersecretion are associated with 
faster lung function decline, increased exacerbation rate 
and increased mortality in COPD. Cough is therefore an 
important feature in COPD in terms of risk stratification 
and prognostication; however, the impact of this symp-
tom is underappreciated by clinicians [4]. Patients report 
increased cough preceding an AE-COPD suggesting that 
Abstract 
Purpose Cough is common in chronic obstructive pulmo-
nary disease (COPD) and is associated with frequent exac-
erbations and increased mortality. Cough increases during 
acute exacerbations (AE-COPD), representing a possible 
metric of clinical deterioration. Conventional cough moni-
tors accurately report cough counts over short time periods. 
We describe a novel monitoring system which we used to 
record cough continuously for up to 45 days during AE-
COPD convalescence.
Methods This is a longitudinal, observational study of 
cough monitoring in AE-COPD patients discharged from a 
single teaching hospital. Ambient sound was recorded from 
two sites in the domestic environment and analysed using 
novel cough classifier software. For comparison, the vali-
dated hybrid HACC/LCM cough monitoring system was 
used on days 1, 5, 20 and 45. Patients were asked to record 
symptoms daily using diaries.
Results Cough monitoring data were available for 16 sub-
jects with a total of 568 monitored days. Daily cough count 
fell significantly from mean ± SEM 272.7 ± 54.5 on day 1 
to 110.9 ± 26.3 on day 9 (p < 0.01) before plateauing. The 
absolute cough count detected by the continuous monitor-
ing system was significantly lower than detected by the 
hybrid HACC/LCM system but normalised counts strongly 
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it may be an attractive option for disease monitoring, par-
ticularly as these data can be collected passively, without 
patient input [5, 6].
In light of the significant burden of disease associated 
with COPD, novel strategies have been developed with the 
aim of improving patient management. The use of technol-
ogy to monitor patients in their homes (telemonitoring) is 
one of these strategies. However, there is no compelling 
evidence that current telemonitoring methods in COPD are 
capable of identifying clinical deterioration early or pre-
venting adverse outcomes including exacerbations requir-
ing hospital admission or death [7–9]. A possible explana-
tion for this is the inability of current monitoring strategies 
to accurately identify early clinical deterioration [7]. This 
may in part be due to the lack of useful objective physio-
logical biomarkers of disease activity. Remote cough moni-
toring has potential to change this. However, existing cough 
monitors are generally worn devices that are designed to 
monitor short time periods. We have previously reported 
the ability of a hybrid cough monitoring system consisting 
of the hull automated cough counter (HACC) and Leices-
ter Cough Monitor software (LCM) to detect a significant 
fall in cough frequency following AE-COPD when meas-
ured on days 1, 5, 20 and 45 [10]. However, to turn these 
observations into a practical monitor for the early detection 
of symptom worsening before exacerbation, continuous 
real-time analysis of cough frequency is required. Here we 
report the results of a cough monitoring system that records 
ambient sound using remote microphones and analyses 
cough frequency using a novel semi-automated cough clas-
sifier. This passive monitoring requires no patient compli-
ance but is limited to those who are predominantly house-
bound. We validate this system against the hybrid HACC/
LCM system and explore its capability to monitor daily 
cough frequency and detect meaningful change in the 
domestic environment.
Methods
Study Design and Subject Selection
This is a longitudinal, observational study of continuous 
remote cough monitoring using a novel cough monitor-
ing system during AE-COPD convalescence. Inclusion 
criteria have been reported in brief previously [10]. Con-
secutive patients admitted to a single teaching hospital 
with an AE-COPD associated with increased cough and 
one more of breathlessness, increased sputum volume, or 
purulence were recruited to the study. Inclusion criteria 
stated that subjects should have a pre-existing diagnosis 
of COPD, be aged between 40 and 80 years and have a 
10 or more pack-years of smoking history. Subjects were 
excluded if they had experienced an AE-COPD within 
the preceding 8 weeks or if they had clinically significant 
or unstable concurrent disease. The study protocol was 
approved by the local research ethics committee (LREC 
Number 11/NW/0643 and R&D Number R1229).
Study Protocol
Continuous cough monitoring was undertaken in the 
patient’s home for 45 days following hospital discharge. 
The continuous monitoring system was composed of 
two laptop computers (Dell E6410, Dell, TX, USA) with 
attached microphones. Systems were positioned in the 
patients’ bedroom and a second room where the patient 
reported spending most of their time during the day. 
Audio captured by the remote microphones was stored 
on the laptop computer and subsequently analysed using 
bespoke semi-automated cough classifier software.
The bespoke cough classifier software works by 
extracting audio features from the full audio stream. The 
audio features are both temporal (e.g. total energy) and 
spectral (e.g. spectral tilt) where the latter is obtained 
using a frequency transformation on a perceptually rel-
evant frequency scale. The cough classifier software 
was trained using a semi-supervised machine learn-
ing approach where a relatively short epoch of data was 
annotated by a member of the study team (1–2 days 
audio data contained an adequate number of coughs for 
classifier training). This was performed for each par-
ticipant and site as different rooms have unique acoustic 
signatures. The training process required 3–4  h human 
involvement per subject. A representative illustration of 
the audio features of a single cough event is presented 
Fig. 1  An example of a single cough recorded in the bedroom of 
patient 12. The audio sampling rate was 22,050 Hz
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in Fig.  1. The trained classifier software was then used 
to detect the coughs in the entire audio stream (up to 45 
days). The number of detected cough events was reported 
over 24 h (midnight to midnight). The sensitivity of the 
classifier software was deliberately minimised in favour 
of high specificity and thus positive predictive value. 
This approach was adopted to optimise trend analysis.
On days 1, 5, 20 and 45 following hospital discharge, the 
patients underwent additional monitoring using a validated, 
hybrid cough monitoring system composed of the HACC 
and LCM software as previously described [10]. The cough 
counts obtained were compared with those obtained during 
the same time period using the continuous monitoring sys-
tem with the aim of evaluating the consistency of sensitiv-
ity and therefore the ability to detect trends.
In addition to cough monitoring, subjects completed 
daily diary cards reporting symptoms of shortness of 
breath, cough, sputum colour, chest tightness and sleep 
disturbance using a 5-point Likert scale. On days 1, 5, 20 
and 45, the subjects also undertook home FEV1 monitoring 
using a hand-held spirometer (Vitallograph, UK) and com-
pleted the Leicester Cough Questionnaire (LCQ), COPD 
Assessment Test (CAT) and Hull Airways Reflux Question-
naire (HARQ). The results of these latter assessments have 
been reported previously [10].
Data Analysis
Continuous Cough Monitoring
For each detected cough, a time stamp was created. Time 
stamps were counted over a full day denoted by d, with 
d = 0 identifying the day of discharge. With the purpose 
of detecting trends, these counts were smoothed over time 
using the mean data over the prior and subsequent 2 days. 
This creates a delay of 2 days in the processing chain. The 
resulting smoothed value is denoted as C(d).
Correlation Between Continuous Cough Monitoring, 
the HACC/LCM Cough Monitor and Symptoms
The cough counts obtained by the continuous monitor-
ing system and the hybrid HACC/LCM system were 
mean normalised to correct for the different sensitivity 
of the two systems. The correlation was estimated using 
Pearson’s correlation coefficient (r). The difference in 
absolute cough count between HACC/LCM and the con-
tinuous cough monitoring system was analysed using 
the Mann–Whitney U test. The change in cough fre-
quency and subjective cough scores were analysed using 
repeated measures ANOVA. For the purposes of this lat-
ter analysis, missing data were imputed as the subsequent 
available measurement. In the event of no subsequent 
measurements being available, the last available measure-
ment was used. Pearson’s correlation coefficient was used 
to assess the correlation between cough count, symptoms 
scores, quality-of-life questionnaires and home FEV1 
measurement.
Results
A total of 24 subjects were screened with 19 subjects 
entering the study. One subject withdrew prior to com-
mencing monitoring and no data were available for two 
subjects due to device failure (Table 1).
Continuous cough monitoring data were available for 
16 subjects with a total of 568 monitored days. HACC/
LCM monitoring data undertaken on days 1, 5, 20 and 
45 were available for 18 subjects with a total of 63 moni-
tored days. Time-aligned cough monitoring data from 
both HACC/LCM and the continuous cough monitor-
ing system were available for 47 monitored days (16 
subjects). Paired continuous cough monitoring data and 
symptom scores were available for 14 subjects (45 moni-
tored days). The most common reason for missing data 
was device failure resulting from loss of power. Patient 
readmission to hospital was another reason for missing 
data.
Table 1  Subject characteristics
SABA short-acting beta-2 agonist, SAMA short-acting muscarinic 
antagonist, LABA long-acting beta-2 agonist, LAMA long-acting mus-
carinic antagonist, ICS inhaled corticosteroid
a Information missing for 1 patient
Demographic Subjects (%)
Number n = 18
Age (mean ± SD) 68.1 ± 7.3
Gender
 Male 8 (44.4)
 Female 10 (66.6)
FEV1 l/min (mean ± SD) 0.99 ± 0.53
COPD  treatmenta
 SABA 15
 SAMA 1
 LABA 2
 LAMA 13
 ICS 0
 LABA/ICS 14
Smoking status
 Current smoker 7 (38.9)
 Ex-smoker 11 (61.1)
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Continuous Cough Monitoring
Daily cough counts were determined for individual patients 
(an example of an individual patient’s cough monitoring 
data is illustrated in Fig. 2). Mean values were calculated 
for the study population. Mean daily cough count fell sig-
nificantly during the first 9 days from a mean ± SEM of 
272.7 ± 54.5 on day 1 to 110.9 ± 26.3 on day 9 (p = 0.006). 
The mean daily cough count then appeared to plateau dem-
onstrating day-to-day variation with a gradual declining 
trend to day 45 (Fig. 3).
Correlation Between Continuous Cough Monitoring 
and the Hybrid HACC/LCM Cough Monitor
The absolute mean daily cough count was significantly 
lower using the continuous monitoring system compared 
with the validated HACC/LCM system (Fig. 4, p = 0.005). 
There was a strong correlation between the mean normal-
ised cough counts generated by the two cough monitoring 
systems (r = 0.88, p < 0.0001) (Fig. 5).
The mean ± SEM sensitivity of the continuous cough 
monitoring system was 50.7 ± 20.22% compared to the 
HACC/LCM system. We observed a considerable degree of 
interpatient variability in sensitivity; however, the intrapa-
tient correlation was strong. There was no significant tem-
poral change in sensitivity and specificity of the monitors 
throughout the study.
Correlation Between Daily Cough Count 
and Symptoms
The subjective cough score decreased significantly during 
the first 7 days of monitoring (mean ± SEM cough score 
2.56 ± 0.53 on day 1 and 1.92 ± 0.35 on day 7, p = 0.001). 
However, subjective cough scores only moderately corre-
lated with objective daily cough counts (median r = 0.46 
IQR 0.36–0.55). Objective cough counts showed the 
greater degree of change during recovery but subjective 
counts returned to convalescent levels sooner. Objective 
cough count did not correlate with other daily reported 
symptoms including shortness of breath (median r = 0.22 
IQR −00.5 to 0.32), chest tightness (median r = 0.16 IQR 
00.06 to 0.38), disturbed sleep (median r = 0.13 IQR −0.12 
Fig. 2  Graph representing the actual daily cough count (stars) and 
smoothed cough count (thick line) for an individual subject during 
AE-COPD convalescence. The thin lines represent the maximum and 
minimum of the actual daily cough count over 3 consecutive days
Fig. 3  Mean daily cough count 
of all study participants (circles) 
and the 3-day rolling mean 
trend line (dotted line) (n = 16)
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to 0.25), or sputum colour (median r = 0.04 IQR −0.13 to 
0.25).
Discussion
Current COPD monitoring strategies use a variety of symp-
tom scores and measurement of basic physiological metrics 
including pulse rate, oxygen saturation and home spirom-
etry. A goal of telemonitoring in COPD is the early iden-
tification of exacerbations facilitating timely intervention. 
There have been attempts to develop new tools to iden-
tify exacerbations including symptom scores such as the 
EXACT-PRO [11]; however, their utility in telemonitoring 
remains unclear and systems that rely predominantly on 
reported symptoms suffer from their subjective nature with 
the risk of ceiling effects and questionnaire fatigue. Objec-
tive measures therefore remain important. However, it has 
been demonstrated that the analysis of the commonly meas-
ured variables rarely identifies a clear distinction between 
normality, technical error, isolated bad days as part of day-
to-day variation and exacerbations [7]. It has been reported 
that a composite score reflecting mean fall in oxygen sat-
uration and rise in heart rate may aid in the identification 
of exacerbations over day-to-day variability [12], but this 
has not been confirmed in later studies [7]. Home spirom-
etry has not been demonstrated to add additional use-
ful information, and we have found poor compliance and 
poor performance confounding its utility [10]. A reliable 
objective measure that collects the data in a passive man-
ner, not requiring regular patient involvement, is therefore 
desirable.
In this study, we demonstrate that it is possible to moni-
tor trends in cough frequency using a device that records 
ambient sound within a patient’s home. Although the abil-
ity of the continuous monitoring system to identify abso-
lute cough counts was significantly lower than that of the 
hybrid HACC/LCM cough monitor, it was clearly capa-
ble of identifying trends in cough frequency. A reduction 
in cough frequency over the first 9–10 days of AE-COPD 
convalescence with a gradual decline up until day 45 was 
detected. Although there was some interpatient variability 
in terms of cough detection sensitivity, the intrapatient cor-
relation was generally very high. Thus, trends could be reli-
ably identified.
Similar to previous reports, there was only a moderate 
correlation between the patient-reported symptom of cough 
and objective cough monitoring [13]. Although the subjec-
tive cough score decreased during the first 7 days of AE-
COPD convalescence, the magnitude of change in mean 
score was less than 1 full point on the Likert scale, making 
it difficult to differentiate meaningful change from day-to-
day variation for an individual patient. The magnitude of 
change in mean cough frequency between day 1 and day 7 
was 119 coughs per 24 h representing a 40% reduction in 
cough frequency.
Objective measurement of cough frequency in COPD 
patients represents a novel metric for disease monitor-
ing with the potential to enhance the capability of existing 
telemonitoring algorithms to detect true deterioration in 
clinical state. We believe that the utility of this technology 
is in monitoring trends in an individual patient’s cough fre-
quency rather than absolute cough counting.
This study is small with relatively few patients. The 
requirement for patients to report a cough at study entry 
introduces selection bias to those with a subjective increase 
in cough associated with their AE-COPD. The utility of 
Fig. 4  Mean cough count using HACC/LCM system and time-
aligned mean cough count using the continuous monitoring (CM) 
system on days 1, 5, 20 and 45 following hospital discharge
Fig. 5  Correlation between mean normalised HACC/LCM cough 
count on days 1, 5, 20 and 45 and time-aligned mean normalised con-
tinuous monitoring (CM) system cough counts
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cough monitoring in COPD patients without a prominent 
cough at the time of exacerbation is therefore unknown. 
Recruitment to the study was challenging because poten-
tial participants were put off by the privacy implications 
of continuous recording of sound within their home. Real-
time, automated analysis in order to negate the need for 
continuous sound recording would improve acceptability to 
patients. It is possible that patients may have consciously 
modified their cough frequency because of an awareness of 
being monitored. However, we feel that this is very unlikely 
given the unobtrusive and continuous nature of the moni-
toring system and long-term duration. The strong correla-
tion between day and night cough counts that we have pre-
viously reported using the HACC/LCM system supports 
the validity of our data as any conscious modification of 
cough would be more likely during the day than at night 
[10]. For the purposes of analysing the change in objec-
tive cough frequency and subjective cough scores, missing 
data were replaced by the next available data point for that 
subject. This is likely to underestimate the significance of 
change over time and therefore we feel that the significant 
change observed in this study is valid.
Cough monitoring in this study is limited to AE-COPD 
convalescence and therefore we cannot evaluate the ability 
of the monitoring system to detect clinical change in the 
period preceding AE-COPD. Prospective studies of devices 
with inbuilt real-time analysis will be required to dem-
onstrate the practical application of the technology in the 
home monitoring of COPD.
Conclusion
Cough frequency declines significantly following AE-
COPD and the reducing trend can be detected using con-
tinuous ambient sound recording and novel cough classifier 
software. Objective measurement of cough frequency in 
COPD patients has potential to enhance the capability of 
existing telemonitoring algorithms to detect true deteriora-
tion in clinical state.
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